After several inspections, the cease and desist notice was lifted in December 2022
A network meta-analysis of 22 RCTs covering 2,258 participants found GLP-1 receptor agonists reduced lean mass by a mean of 0.86 kg, with lean mass comprising roughly 25% of total weight lost across agents
Likewise, advances in materials science, nanotechnology, and microfabrication have opened up new design possibilities for microneedle-mediated drug delivery systems, all of which are contributing to the safety, efficacy, and usability of these platforms [35]
2025 Jul 7;15(7):128
Making GLP-1 Treatment Accessible The reality is stark: brand-name Ozempic at $969 monthly is financially impossible for most people without substantial insurance assistance
The question is not which company has a perfect record, because neither does